title: Primary thyroid marginal zone B-cell lymphoma in a patient with psoriatic arthritis treated with etanercept.
authors.affiliation: Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea.
authors.forename: Hyunju
authors.initials: H
authors.lastname: Jin
authors.affiliation: Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea.
authors.forename: Hyun-Ho
authors.initials: HH
authors.lastname: Cho
authors.affiliation: Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea.
authors.forename: Won-Jeong
authors.initials: WJ
authors.lastname: Kim
authors.affiliation: Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea.
authors.forename: Je-Ho
authors.initials: JH
authors.lastname: Mun
authors.affiliation: Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea.
authors.forename: Margaret
authors.initials: M
authors.lastname: Song
authors.affiliation: Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea.
authors.forename: Hoon-Soo
authors.initials: HS
authors.lastname: Kim
authors.affiliation: Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea.
authors.forename: Hyun-Chang
authors.initials: HC
authors.lastname: Ko
authors.affiliation: Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea; Biomedical Research Institute, Pusan National University, Busan, Korea.
authors.forename: Moon-Bum
authors.initials: MB
authors.lastname: Kim
authors.affiliation: Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea; Biomedical Research Institute, Pusan National University, Busan, Korea. Electronic address: dockbs@pusan.ac.kr.
authors.forename: Byung-Soo
authors.initials: BS
authors.lastname: Kim
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D015535:Arthritis, Psoriatic / Q000175:diagnosis / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D000068800:Etanercept; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects* / Q000627:therapeutic use; D018442:Lymphoma, B-Cell, Marginal Zone / Q000209:etiology* / Q000473:pathology / Q000628:therapy; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D011565:Psoriasis / Q000175:diagnosis / Q000188:drug therapy*; D018714:Radiotherapy, Adjuvant; D035583:Rare Diseases; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D012008:Recurrence; D019233:Retreatment; D018570:Risk Assessment; D012720:Severity of Illness Index; D013964:Thyroid Neoplasms / Q000209:etiology* / Q000473:pathology / Q000628:therapy; D013965:Thyroidectomy / Q000379:methods; D016312:Treatment Refusal
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept; D008727:Methotrexate